For the quarter ending 2025-09-30, DRMA had -$1,816,803 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total research and development | 504,387 | - |
| Total selling, general and administrative | 3,469,842 | - |
| Interest income | 68,681 | - |
| Net loss | -1,691,989 | -4,004,680 |
| Stock-based compensation | 37,841 | 76,422 |
| Prepaid expenses and other current assets | 247,697 | -212,732 |
| Accounts payable | 52,727 | -356,816 |
| Accrued and other current liabilities | 45,303 | -552,205 |
| Total adjustments to reconcile net loss to net cash used in operations | -111,826 | -619,867 |
| Net cash used in operating activities | -1,803,815 | -4,624,547 |
| Proceeds from issuance of common stock and warrants, net of issuance costs | -12,621 | 7,993,425 |
| Payment of prior period issuance costs | 0 | 50,495 |
| Issuance costs paid setting up atm agreement | - | 0 |
| Proceeds from exercise of pre-funded warrants | 0 | 977 |
| Payment for fractional shares in reverse stock split | -367 | 0 |
| Net cash provided by financing activities | -12,988 | 7,943,907 |
| Net increase (decrease) in cash and cash equivalents | -1,816,803 | 3,319,360 |
| Cash and cash equivalents at beginning of period | 3,161,570 | - |
| Cash and cash equivalents at end of period | 4,664,127 | - |
Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc. (DRMA)